A randomized phase III trial of stereotactic ablative radiotherapy for patients with up to 10 oligometastases and a synchronous primary tumor (SABR-SYNC): study protocol

Table 1 Selected randomized trials of ablative therapies for patients with oligometastases

Histology	Trial Name / Author	Intervention	Benefit Demonstrated
NSCLC	Gomez [6]	RT or surgery	OS, PFS
	Iyengar [7]	SABR	PFS
	SINDAS / Wang [10]	SABR	OS, PFS
	Peng [11]	SABR	OS, PFS
Prostate	STOMP / Ost [8]	RT or surgery	ADT-free survival
	ORIOLE / Phillips [9]	SABR	PFS
	EXTEND / Tang [12]	RT / SABR	PFS
	ARTO / Francolini [13]	SABR	PFS
Colorectal	EORTC 40004 / Ruers [14]	RFA (liver)	OS, PFS
Colorectal	PulMiCC / Treasure [15]	Surgery (lung)	None
Pancreas	EXTEND / Ludmir [16]	RT / SABR	PFS
Breast	BR002 / Chmura [17]	SABR or surgery	None
Esophageal	ESO-Shanghai-13 / Liu [18]	RT, surgery, TA	OS, PFS
Multiple	SABR-COMET / Palma [19]	SABR	OS, PFS
Multiple	CORE / Khoo [20]	SABR	PFS

NSCLC non-small cell lung cancer, RT radiotherapy, SABR stereotactic ablative radiotherapy, RFA radiofrequency ablation, TA thermal ablation, OS overall survival, PFS progression-free survival, ADT androgen deprivation therapy

ISSN: 1472-684X